Phibro Animal Health Corporation $PAHC Holdings Trimmed by Villanova Investment Management Co LLC

Key Points

• Villanova Investment Management Co LLC has reduced its stake in Phibro Animal Health Corporation by 65.9%, selling 62,365 shares and now holding 32,279 shares worth approximately $689,000.
• Phibro Animal Health reported a quarterly earnings per share of $0.57, exceeding analysts' expectations of $0.52, along with revenue of $378.70 million for the quarter.
• The company recently declared a quarterly dividend of $0.12 per share, with an annualized yield of 1.2%, to be paid to shareholders on September 24th.

Villanova Investment Management Co LLC lessened its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 65.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,279 shares of the company's stock after selling 62,365 shares during the quarter. Phibro Animal Health comprises about 1.9% of Villanova Investment Management Co LLC's investment portfolio, making the stock its 18th biggest position. Villanova Investment Management Co LLC owned about 0.08% of Phibro Animal Health worth $689,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Man Group plc purchased a new position in shares of Phibro Animal Health during the 4th quarter worth $501,000. GAMMA Investing LLC lifted its stake in shares of Phibro Animal Health by 2,011.4% during the 1st quarter. GAMMA Investing LLC now owns 36,718 shares of the company's stock worth $784,000 after purchasing an additional 34,979 shares during the period. LPL Financial LLC lifted its stake in shares of Phibro Animal Health by 46.8% during the 1st quarter. LPL Financial LLC now owns 128,335 shares of the company's stock worth $2,741,000 after purchasing an additional 40,889 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after purchasing an additional 1,589 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in shares of Phibro Animal Health by 21.4% during the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after purchasing an additional 103,618 shares during the period. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Stock Performance

Shares of PAHC traded down $0.36 during mid-day trading on Tuesday, reaching $39.17. 66,445 shares of the company's stock traded hands, compared to its average volume of 275,318. The business's 50-day moving average price is $32.18 and its 200-day moving average price is $25.67. The stock has a market capitalization of $1.59 billion, a P/E ratio of 33.17, a price-to-earnings-growth ratio of 1.18 and a beta of 0.88. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $41.57.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $378.70 million for the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be issued a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health's payout ratio is presently 40.68%.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of recent analyst reports. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research note on Thursday, August 28th. Bank of America increased their target price on Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research report on Friday, August 29th. BNP Paribas raised Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price on the stock in a research report on Monday, June 16th. Finally, JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Reduce" and an average price target of $28.40.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 3,520 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $41.29, for a total transaction of $145,340.80. Following the sale, the chief executive officer owned 41,880 shares of the company's stock, valued at $1,729,225.20. The trade was a 7.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 50.07% of the stock is currently owned by insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.